Kusajili is updated regularly with data from the following sources: ACTRN, EU Clinical Trials Register, GlaxoSmithKline (GSK) Clinical Study Register, Clinical Trials Search Portal provides, ISRCTN, JPRN, ClinicalTrials - NCT, Pfizer, Takeda, Pubmed.
Regularly we prefer 3 studies to help the inclusion of patients.
This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of an experimental therapy called CTL019 T-cells in pediatric patients with B-cell acute lymphoblastic leukemia, who are chemo-refractory, relapsed after allogeneic SCT, or are otherwise ineligible for allogeneic stem cell transplant.More information
Autologous T cells engineered to express an anti-CD19 chimeric antigen receptor (CAR) with a safety switch will be infused back to patients with B cell malignancies, including lymphoma and leukemia. The patients will be monitored after infusion of anti-CD19 CAR-transduced T cells for adverse events, persistence of anti-CD19 CAR-transduced T cells and treatment efficacy. ...More information
Kusajili is a protean search engine that addresses the need to simplify access to registers and patient inclusions.
Kusajili makes it possible to find in a few clicks, the numerous French and international trials referenced.
Kusajili, associated with MyHomeDoctor, facilitates multicenter clinical trials.
Docteur CRETON, Créateur de KUSAJILI